Company Filing History:
2 out of 1,743 
2 out of 11 
2 out of 6 
Years Active: 2024-2025
Title: Charles-Antoine Guilloux: Innovator in Pulmonary Health
Introduction
Charles-Antoine Guilloux is a notable inventor based in Brest, France. He has made significant contributions to the field of pulmonary health through his innovative research and inventions. With a total of 2 patents, Guilloux has focused on methods that enhance the understanding and prediction of pulmonary infections.
Latest Patents
Guilloux's latest patents revolve around methods for predicting the risk of developing pulmonary colonization and infection. His research involved analyzing the respiratory tract microbiota from sputum samples of 65 patients. The findings revealed that patients who remained uninfected exhibited a three-fold higher abundance of specific bacteria compared to other groups. In particular, one of his inventions relates to a method for predicting the risk of developing pulmonary colonization or infection in subjects suffering from cystic fibrosis. This method comprises measuring the abundance of certain genera of bacteria in biological samples obtained from these subjects.
Career Highlights
Throughout his career, Guilloux has worked with esteemed institutions such as the National Institute of Health and Medical Research (Institut National De La Sante Et De La Recherche Medicale) and the Regional and University Hospital Center of Brest (Centre Hospitalier Regional Et Universitaire De Brest). His work has significantly impacted the understanding of pulmonary health and disease.
Collaborations
Guilloux has collaborated with notable colleagues, including Geneviève Hery-Arnaud and Jérôme Mounier. These collaborations have further enriched his research and contributed to the advancements in his field.
Conclusion
Charles-Antoine Guilloux is a distinguished inventor whose work in predicting pulmonary infections has the potential to improve patient outcomes, particularly for those with cystic fibrosis. His innovative methods and collaborations highlight his commitment to advancing medical research and technology.